NCT06460324View on ClinicalTrials.gov

A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

July 3, 2023

Study Completion Date

July 3, 2023

Conditions
Multiple Sclerosis
Trial Locations (1)

07936

Novartis, East Hanover

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY